Medication info

Pitamint Metreong 15/850 mg

Prescription medicationTabletExpired
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Medix Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, oblong film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Expired

MFDS item code 201902286 · Approved 2019.04.15

This product's status changed to Expired on 2024.04.15. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medication should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is inadequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medication daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this medication may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medication. After initiating this medication or increasing the dose, patients must be carefully monitored for adverse reactions related to fluid retention. This medication should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medication, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
Medix Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-resistant diabetes
  • abnormal blood glucose control
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar levels in patients with type 2 insulin-resistant diabetes. It is specifically utilized when sufficient glycemic control cannot be achieved with monotherapy of metformin or pioglitazone alone, or it can serve as an alternative to the combination of these two drugs. Managing type 2 diabetes requires dietary counseling, weight loss, and regular exercise, and improvements in these lifestyle habits are essential for enhancing the efficacy of pharmacotherapy. Therefore, this medication is effectively utilized to improve blood glucose control in conjunction with lifestyle interventions.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medication should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is inadequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medication daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this medication may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medication. After initiating this medication or increasing the dose, patients must be carefully monitored for adverse reactions related to fluid retention. This medication should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medication, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication is comprised of two main components, each of which aids in blood sugar control, but there are important considerations to keep in mind when taking it. First, one component of this medication can cause a serious side effect known as lactic acidosis in patients with impaired kidney function or liver dysfunction. Lactic acidosis is a condition in which lactate accumulates excessively in the bloodstream, causing harm to the body, and while rare, it can be fatal; therefore, regular monitoring of kidney or liver health is essential. Second, this medication can place additional strain on the heart and should not be administered to patients with heart failure or severe heart disease. If symptoms of heart failure arise, medical consultation should be sought immediately, and careful observation of symptoms such as weight gain or edema is necessary. Third, it is advisable not to use this medication in patients with a history of bladder cancer or active bladder cancer. If symptoms such as hematuria or urinary difficulties occur, medical staff should be informed immediately. Fourth, excessive alcohol consumption should be avoided while taking this medication, and temporary discontinuation may be necessary before and after surgery or in cases of acute infections or dehydration. Fifth, although this medication lowers blood sugar levels, caution is warranted as the risk of hypoglycemia may increase when taken with other blood glucose-lowering agents. Sixth, in elderly patients, renal function may decline, thus necessitating dose adjustments and regular monitoring of kidney function. Lastly, women who are pregnant or breastfeeding should not take this medication, and its safety and efficacy in pediatric patients have not been established. Therefore, regular blood tests and observation of symptoms are crucial while taking this medication, and immediate consultation with healthcare professionals should be undertaken if any abnormalities arise.

Side effects

  • lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 40 more
  • congestive heart failure
  • excessive and rapid weight changes
  • dyspnea
  • edema
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower extremity edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • edema
  • decreased vision
  • liver failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal bloating
  • gastroesophageal reflux disease
  • aerophagia
  • increased serum creatinine
  • increased blood urea
  • fractures
  • hypoglycemia
  • abnormal blood glucose
  • gastroenteritis
  • failure of blood sugar control
  • visible hematuria
  • urinary difficulties
  • urgency in urination

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and the storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. By storing it this way, the effectiveness of the medication can be preserved for a longer period.

Appearance and packaging

Appearance

White to grayish-white, oblong film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.